Bio-CDMO Research:CAGR of 12.7% during the forecast period

QY Research Inc. (Global Market Report Research Publisher) announces the release of 2024 latest report "Biopharmaceutical and Bio-CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030". Based on current situation and impact historical analysis (2019-2023) and forecast calculations (2024-2030), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years.



The global Biopharmaceutical and Bio-CDMO revenue was US$ 28160 million in 2023 and is forecast to a readjusted size of US$ 60300 million by 2030 with a CAGR of 13.1% during the review period (2024-2030).



【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】

https://www.qyresearch.com/reports/3271296/biopharmaceutical-and-bio-cdmo



Bio-CDMO Market Summary

Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.

According to the new market research report "Global Bio-CDMO Market Report 2024-2030", published by QYResearch, the global Bio-CDMO market size is projected to reach USD 59.05 billion by 2030, at a CAGR of 12.7% during the forecast period.

Global Bio-CDMO MarketSize(US$ Million), 2019-2030
241223-173046.webp (13 KB)

Above data is based on report from QYResearch: Global Bio-CDMO Market Report 2024-2030 (published in 2024). If you need the latest data, plaese contact QYResearch.



Global Bio-CDMO Top17Players Ranking and Market Share (Ranking is based on the revenue of 2023, continually updated)
241223-173109.webp (21 KB)

Above data is based on report from QYResearch: Global Bio-CDMO Market Report 2024-2030 (published in 2024). If you need the latest data, plaese contact QYResearch.

According to QYResearch Top Players Research Center, the global key manufacturers of Bio-CDMO include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, etc. In 2023, the global top five players had a share approximately 49.0% in terms of revenue.

Bio-CDMO,Global Market Size, Split by Product Segment
241223-173131.webp (20 KB)

Based on or includes research from QYResearch: Global Bio-CDMO Market Report 2024-2030.



Market Drivers:

D1: Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, anfxxd gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.



D2: Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.



D3: Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.



Market Challenges:

C1: High Initial Investment: The setup of facilities with advanced technologies for bioprocessing requires a substantial initial investment. CDMOs need to invest in state-of-the-art equipment, infrastructure, and qualified personnel to meet the stringent requirements of biopharmaceutical manufacturing.



C2: Capacity Constraints: The increasing demand for biopharmaceutical manufacturing services has led to capacity constraints in some cases. CDMOs may face challenges in scaling up production to meet the growing needs of clients, potentially leading to delays in project timelines.



C3: Complexity of Bioprocessing: Biopharmaceutical manufacturing involves complex bioprocessing techniques, such as cell culture and purification. Optimizing these processes for scalability, efficiency, and reproducibility can be challenging, especially for novel and advanced therapies.







The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.



The Biopharmaceutical and Bio-CDMO market is segmented as below:

By Company

Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi AppTech
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals



Segment by Type

Cell and Gene Therapies
Antibodies
Vaccines
Other



Segment by Application

SMBs
Large Companies



Each chapter of the report provides detailed information for readers to further understand the Biopharmaceutical and Bio-CDMO market:

Chapter 1: Introduces the report scope of the Biopharmaceutical and Bio-CDMO report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2019-2030)

Chapter 2: Detailed analysis of Biopharmaceutical and Bio-CDMO manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2019-2024)

Chapter 3: Provides the analysis of various Biopharmaceutical and Bio-CDMO market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2019-2030)

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2019-2030)

Chapter 5: Sales, revenue of Biopharmaceutical and Bio-CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2019-2030)

Chapter 6: Sales, revenue of Biopharmaceutical and Bio-CDMO in country level. It provides sigmate data by Type, and by Application for each country/region.(2019-2030)

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2019-2024)

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.



Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Biopharmaceutical and Bio-CDMO competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Biopharmaceutical and Bio-CDMO comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Biopharmaceutical and Bio-CDMO market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.



Other relevant reports of QYResearch:

Global Biopharmaceutical and Bio-CDMO Market Insights, Forecast to 2030
Global Biopharmaceutical and Bio-CDMO Market Research Report 2024
Biopharmaceutical and Bio-CDMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

About Us：

QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 17 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)  
JP: https://www.qyresearch.co.jp

This release was published on openPR.